Population pharmacokinetics of anidulafungin in critically ill patients

S. Luque, W. Hope, N. Campillo, R. Muñoz-Bermúdez, L. Sorli, J. Barceló-Vidal, E. González-Colominas, F. Alvarez-Lerma, J. R. Masclans, M. Montero, J. P. Horcajada, S. Graua

Research output: Contribution to journalArticleResearch

5 Citations (Scopus)


Copyright © 2019 American Society for Microbiology. All Rights Reserved. A two-compartment pharmacokinetic (PK) population model of anidulafungin was fitted to PK data from 23 critically ill patients (age, 65 years [range, 28 to 81 years]; total body weight [TBW], 75 kg [range, 54 to 168 kg]). TBW was associated with clearance and incorporated into a final population PK model. Simulations suggested that patients with higher TBWs had less-extensive MIC coverage. Dosage escalation may be warranted in patients with high TBWs to ensure optimal drug exposures for treatment of Candida albicans and Candida glabrata infections.
Original languageEnglish
Article numbere00378-19
JournalAntimicrobial Agents and Chemotherapy
Publication statusPublished - 1 Jan 2019


  • Anidulafungin
  • Candida
  • Critical care unit
  • Monte Carlo simulation
  • Pharmacokinetics/pharmacodynamics


Dive into the research topics of 'Population pharmacokinetics of anidulafungin in critically ill patients'. Together they form a unique fingerprint.

Cite this